{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:52:17Z","timestamp":1782604337314,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T00:00:00Z","timestamp":1447459200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Mol Neurosci"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1007\/s12031-015-0682-7","type":"journal-article","created":{"date-parts":[[2015,11,14]],"date-time":"2015-11-14T01:36:56Z","timestamp":1447465016000},"page":"379-387","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Clinical Trials in Spinal and Bulbar Muscular Atrophy\u2014Past, Present, and Future"],"prefix":"10.1007","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2344-5662","authenticated-orcid":false,"given":"Patrick","family":"Weydt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sagnelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Rosenbohm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Fratta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Pradat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert C.","family":"Ludolph","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Pareyson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,11,14]]},"reference":[{"key":"682_CR1","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1093\/brain\/awl096","volume":"129","author":"N Atsuta","year":"2006","unstructured":"Atsuta N (2006) Natural history of spinal and bulbar muscular atrophy (SBMA): a study of 223 Japanese patients. Brain 129:1446\u20131455. doi: 10.1093\/brain\/awl096","journal-title":"Brain"},{"key":"682_CR2","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1001\/archneurol.2011.2308","volume":"69","author":"H Banno","year":"2012","unstructured":"Banno H (2012) Molecular pathophysiology and disease-modifying therapies for spinal and bulbar muscular atrophy. Arch Neurol 69:436. doi: 10.1001\/archneurol.2011.2308","journal-title":"Arch Neurol"},{"key":"682_CR3","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/ana.20735","volume":"59","author":"H Banno","year":"2006","unstructured":"Banno H, Adachi H, Katsuno M et al (2006) Mutant androgen receptor accumulation in spinal and bulbar muscular atrophy scrotal skin: a pathogenic marker. Ann Neurol 59:520\u2013526. doi: 10.1002\/ana.20735","journal-title":"Ann Neurol"},{"key":"682_CR4","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1002\/ana.21540","volume":"65","author":"H Banno","year":"2009","unstructured":"Banno H, Katsuno M, Suzuki K et al (2009) Phase 2 trial of leuprorelin in patients with spinal and bulbar muscular atrophy. Ann Neurol 65:140\u2013150. doi: 10.1002\/ana.21540","journal-title":"Ann Neurol"},{"key":"682_CR5","doi-asserted-by":"crossref","unstructured":"Bates GP, Dorsey R, Gusella JF et al (2015) Huntington disease. Nat Rev Dis Primers 15005\u201321. doi: 10.1038\/nrdp.2015.5","DOI":"10.1038\/nrdp.2015.5"},{"key":"682_CR6","doi-asserted-by":"crossref","unstructured":"Borowsky B, Sampaio C (2014) Experimental therapeutics: moving forward in clinical trials. In: Bates GP, Tabrizi SJ, Jones L (eds) Huntington's disease, 4th edn. Oxford University Press, Oxford, p 462\u2013502","DOI":"10.1093\/med\/9780199929146.003.0017"},{"key":"682_CR7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000351153","volume":"41","author":"A Chio","year":"2013","unstructured":"Chio A, Logroscino G, Traynor BJ et al (2013) Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the published literature. Neuroepidemiology 41:118\u2013130. doi: 10.1159\/000351153","journal-title":"Neuroepidemiology"},{"key":"682_CR8","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/S1474-4422(10)70321-5","volume":"10","author":"BSNADK Fern\u00e1ndez-Rhodes LE","year":"2011","unstructured":"Fern\u00e1ndez-Rhodes LE BSNADK, MD MJW et al (2011) Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol 10:140\u2013147. doi: 10.1016\/S1474-4422(10)70321-5","journal-title":"Lancet Neurol."},{"key":"682_CR9","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.pneurobio.2012.05.012","volume":"99","author":"KH Fischbeck","year":"2012","unstructured":"Fischbeck KH (2012) Developing treatment for spinal and bulbar muscular atrophy. Prog Neurobiol 99:257\u2013261. doi: 10.1016\/j.pneurobio.2012.05.012","journal-title":"Prog Neurobiol"},{"key":"682_CR10","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1212\/WNL.0000000000000507","volume":"82","author":"P Fratta","year":"2014","unstructured":"Fratta P, Nirmalananthan N, Masset L et al (2014) Correlation of clinical and molecular features in spinal bulbar muscular atrophy. Neurology 82:2077\u20132084. doi: 10.1212\/WNL.0000000000000507","journal-title":"Neurology"},{"key":"682_CR11","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.nmd.2015.03.008","volume":"25","author":"A Hashizume","year":"2015","unstructured":"Hashizume A, Katsuno M, Suzuki K et al (2015) A functional scale for spinal and bulbar muscular atrophy: cross-sectional and longitudinal study. Neuromuscul Disord 25:554\u2013562. doi: 10.1016\/j.nmd.2015.03.008","journal-title":"Neuromuscul Disord"},{"key":"682_CR12","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1038\/nm878","volume":"9","author":"M Katsuno","year":"2003","unstructured":"Katsuno M, Adachi H, Doyu M et al (2003) Leuprorelin rescues polyglutamine-dependent phenotypes in a transgenic mouse model of spinal and bulbar muscular atrophy. Nat Med 9:768\u2013773. doi: 10.1038\/nm878","journal-title":"Nat Med"},{"key":"682_CR13","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S1474-4422(10)70182-4","volume":"9","author":"M Katsuno","year":"2010","unstructured":"Katsuno M, Banno H, Suzuki K et al (2010) Efficacy and safety of leuprorelin in patients with spinal and bulbar muscular atrophy (JASMITT study): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol 9:875\u2013884. doi: 10.1016\/S1474-4422(10)70182-4","journal-title":"Lancet Neurol."},{"key":"682_CR14","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.pneurobio.2012.05.007","volume":"99","author":"M Katsuno","year":"2012","unstructured":"Katsuno M, Tanaka F, Adachi H et al (2012) Pathogenesis and therapy of spinal and bulbar muscular atrophy (SBMA). Prog Neurobiol 99:246\u2013256. doi: 10.1016\/j.pneurobio.2012.05.007","journal-title":"Prog Neurobiol"},{"key":"682_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/352077a0","volume":"352","author":"AR Spada La","year":"1991","unstructured":"La Spada AR, Wilson EM, Lubahn DB et al (1991) Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 352:77\u201379. doi: 10.1038\/352077a0","journal-title":"Nature"},{"key":"682_CR16","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S0002-9440(10)65612-X","volume":"153","author":"M Li","year":"1998","unstructured":"Li M, Nakagomi Y, Kobayashi Y et al (1998) Nonneural nuclear inclusions of androgen receptor protein in spinal and bulbar muscular atrophy. Am J Pathol 153:695\u2013701. doi: 10.1016\/S0002-9440(10)65612-X","journal-title":"Am J Pathol"},{"key":"682_CR17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1152\/physrev.00028.2007","volume":"88","author":"GS Lynch","year":"2008","unstructured":"Lynch GS, Ryall JG (2008) Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease. Physiol Rev 88:729\u2013767. doi: 10.1152\/physrev.00028.2007","journal-title":"Physiol Rev"},{"key":"682_CR18","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.neuron.2009.07.019","volume":"63","author":"I Palazzolo","year":"2009","unstructured":"Palazzolo I, Stack C, Kong L et al (2009) Overexpression of IGF-1 in muscle attenuates disease in a mouse model of spinal and bulbar muscular atrophy. Neuron 63:316\u2013328. doi: 10.1016\/j.neuron.2009.07.019","journal-title":"Neuron"},{"key":"682_CR19","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.neuron.2009.07.024","volume":"63","author":"T Papanikolaou","year":"2009","unstructured":"Papanikolaou T, Ellerby LM (2009) IGF-1: elixir for motor neuron diseases. Neuron 63:277\u2013278. doi: 10.1016\/j.neuron.2009.07.024","journal-title":"Neuron"},{"key":"682_CR20","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.nmd.2015.06.462","volume":"25","author":"M Pennuto","year":"2015","unstructured":"Pennuto M, Greensmith L, Pradat P-F et al (2015) 210th ENMC International Workshop: research and clinical management of patients with spinal and bulbar muscular atrophy, 27\u201329 March, 2015, Naarden, The Netherlands. Neuromuscul Disord 25:802\u2013812. doi: 10.1016\/j.nmd.2015.06.462","journal-title":"Neuromuscul Disord"},{"key":"682_CR21","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1212\/01.wnl.0000341274.61236.02","volume":"72","author":"N Preisler","year":"2009","unstructured":"Preisler N, Andersen G, Th\u00f8gersen F et al (2009) Effect of aerobic training in patients with spinal and bulbar muscular atrophy (Kennedy disease). Neurology 72:317\u2013323. doi: 10.1212\/01.wnl.0000341274.61236.02","journal-title":"Neurology"},{"key":"682_CR22","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1212\/WNL.0b013e318295d766","volume":"80","author":"G Querin","year":"2013","unstructured":"Querin G, D\u2019Ascenzo C, Peterle E et al (2013) Pilot trial of clenbuterol in spinal and bulbar muscular atrophy. Neurology 80:2095\u20132098. doi: 10.1212\/WNL.0b013e318295d766","journal-title":"Neurology"},{"key":"682_CR23","doi-asserted-by":"crossref","unstructured":"Rocchi A, Pennuto M (2013) New routes to therapy for spinal and bulbar muscular atrophy. J Mol Neurosci. doi: 10.1007\/s12031-013-9978-7","DOI":"10.1007\/s12031-013-9978-7"},{"key":"682_CR24","doi-asserted-by":"crossref","first-page":"5985","DOI":"10.1093\/hmg\/ddv300","volume":"24","author":"K Sahashi","year":"2015","unstructured":"Sahashi K, Katsuno M, Hung G et al (2015) Silencing neuronal mutant androgen receptor in a mouse model of spinal and bulbar muscular atrophy. Hum Mol Genet 24:5985\u20135994. doi: 10.1093\/hmg\/ddv300","journal-title":"Hum Mol Genet"},{"key":"682_CR25","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1002\/acn3.208","volume":"2","author":"JA Shrader","year":"2015","unstructured":"Shrader JA, Kats I, Kokkinis A et al (2015) A randomized controlled trial of exercise in spinal and bulbar muscular atrophy. Ann Clin Transl Neurol 2:739\u2013747. doi: 10.1002\/acn3.208","journal-title":"Ann Clin Transl Neurol"},{"key":"682_CR26","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1212\/01.wnl.0000250358.32199.24","volume":"68","author":"M-L Sveen","year":"2007","unstructured":"Sveen M-L, Jeppesen TD, Hauerslev S et al (2007) Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology 68:59\u201361. doi: 10.1212\/01.wnl.0000250358.32199.24","journal-title":"Neurology"},{"key":"682_CR27","doi-asserted-by":"crossref","first-page":"e70993","DOI":"10.1371\/journal.pone.0070993","volume":"8","author":"TA Willis","year":"2013","unstructured":"Willis TA, Hollingsworth KG, Coombs A et al (2013) Quantitative muscle MRI as an assessment tool for monitoring disease progression in LGMD2I: a multicentre longitudinal study. PLoS One 8:e70993\u20137. doi: 10.1371\/journal.pone.0070993","journal-title":"PLoS One"}],"container-title":["Journal of Molecular Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-015-0682-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12031-015-0682-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12031-015-0682-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T22:25:17Z","timestamp":1559427917000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12031-015-0682-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11,14]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["682"],"URL":"https:\/\/doi.org\/10.1007\/s12031-015-0682-7","relation":{},"ISSN":["0895-8696","1559-1166"],"issn-type":[{"value":"0895-8696","type":"print"},{"value":"1559-1166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,14]]}}}